Image from Google Jackets

A patent review of FGFR4 selective inhibition in cancer (2007-2018)

Tipo de material: TextoTextoSeries ; Expert Opinion on Therapeutic patents, 29(6), p.429-438, 2019Trabajos contenidos:
  • Quintanal-Villalonga, A
  • Ferrer, I
  • Molina-Pinelo, S
  • Paz-Ares, L
Tema(s): Recursos en línea: Resumen: FGFR4 is a tyrosine kinase receptor which, under physiological conditions, is activated upon ligand binding in a highly regulated manner. This triggers downstream signaling related to proliferation and apoptosis resistance as well as other physiological processes. Many molecular alterations of the receptor and its ligands, specially FGF19, have been reported in several types of cancer, with special relevance in hepatocellular carcinoma. In addition, these have also been detected in other solid malignancies, including lung, breast, or colon cancer, among others.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Collection Call number Status Date due Barcode
Documentos solicitados Documentos solicitados CICY Documento préstamo interbibliotecario Ref1 B-18018 (Browse shelf(Opens below)) Available

FGFR4 is a tyrosine kinase receptor which, under physiological conditions, is activated upon ligand binding in a highly regulated manner. This triggers downstream signaling related to proliferation and apoptosis resistance as well as other physiological processes. Many molecular alterations of the receptor and its ligands, specially FGF19, have been reported in several types of cancer, with special relevance in hepatocellular carcinoma. In addition, these have also been detected in other solid malignancies, including lung, breast, or colon cancer, among others.

There are no comments on this title.

to post a comment.